Vardenafil Hydrochloride Tablet
Product Images NDC 0527-2801

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Vardenafil Hydrochloride (NDC 0527-2801). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lannett Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 mg Bottle Label V2 04 2020

Packaging label for Vardenafil Hydrochloride Tablets 10 mg oral dosage form, containing 30 tablets. The label shows the product name, strength, and prescription status (Rx Only). Manufactured by Rivopharm SA in Switzerland and distributed by Lannett Company, Inc. Additional text includes usage instructions, storage recommendations, and a barcode. The Lannett logo is present on the label.*

FDA Label Image

2.5 mg Bottle Label V2 04 2020

Label for Vardenafil Hydrochloride Tablets 2.5 mg by Lannett Company, Inc. This oral tablet package contains 30 tablets. The label includes manufacturer information (Rivopharm SA, Switzerland), a barcode, dosage strength, and storage instructions. It also states prescription use only and includes data matrix area with placeholders for GTIN, SN, EXP, and LOT details.*

FDA Label Image

20 mg Bottle Label V2 04 2020

Vardenafil Hydrochloride Tablets 20 mg label showing the product name, strength, and dosage form. The label indicates 30 tablets per bottle, distributed by Lannett Company, Inc. The manufacturer is Rivopharm SA in Manno, Switzerland. Storage recommendations and dosage instructions are included in smaller text on the right side of the label.*

FDA Label Image

5 mg Bottle Label V2 04 2020

Label for Vardenafil Hydrochloride Tablets 5 mg, oral tablets available in a bottle of 30 tablets. The label shows manufacturing information by Rivopharm SA in Switzerland and distribution by Lannett Company, Inc. It includes dosage instructions and storage recommendations, along with a barcode and National Drug Code (NDC) 0527-2801-32.*

FDA Label Image

Chemical Structure (Vardenafil Figure 1)

Chemical structure diagram of Vardenafil Hydrochloride depicting its molecular formula and hydrochloride and hydrate components (x HCl x 3H2O). The structure shows characteristic rings and functional groups typical of Vardenafil's molecular composition.*

FDA Label Image

Figure 1 (Vardenafil Figure 2)

A set of three line graphs depicting the mean maximal change in systolic blood pressure, diastolic blood pressure, and heart rate over different timings of Vardenafil treatment before NTG. The x-axis represents time intervals (24h, 8h, 4h, 1h), and the y-axis shows the mean maximal change for each parameter with error bars.*

FDA Label Image

Figure 2 (Vardenafil Figure 3)

A line graph showing mean change in mmHg over a 6-hour period comparing placebo and Vardenafil 5 mg under two conditions: simultaneous and 6-hour separation. The y-axis indicates mean change (mmHg) from -15 to 15, and the x-axis shows time in hours from 0 to 6. Four data sets are plotted with different markers representing placebo and Vardenafil 5 mg at each condition.*

FDA Label Image

Figure 3 (Vardenafil Figure 4)

A line graph depicting mean change in mmHg over time in hours for placebo and Vardenafil 5 mg under simultaneous and 6-hour separation dosing conditions. The x-axis shows time in hours from 0 to 6, and the y-axis shows mean change in mmHg ranging approximately from -15 to 15, comparing blood pressure effects over time among the four groups.*

FDA Label Image

Figure 4 (Vardenafil Figure 5)

A line graph showing mean change in mmHg over time (hours) for Vardenafil at 10 mg and 20 mg doses compared to placebo in two stages. The x-axis represents time in hours (0 to 6), and the y-axis represents mean change in mmHg (-10 to 5). Solid and dashed lines with different markers distinguish the treatment groups and stages.*

FDA Label Image

Figure 5 (Vardenafil Figure 6)

A line graph showing mean change in mmHg over 6 hours comparing Vardenafil 5 mg and 10 mg with placebo in two stages. The x-axis represents time in hours, and the y-axis shows mean blood pressure change. Lines indicate variations in pressure for Vardenafil doses and placebo groups across the time points.*

FDA Label Image

Figure 6 (Vardenafil Figure 7)

A line graph titled "TERAZOSIN" showing the mean change in mmHg on the y-axis and time in hours on the x-axis. The graph compares placebo, 10 mg vardenafil, and 20 mg vardenafil under two conditions: 6-hour separation and simultaneous administration, using different symbols and line styles for each group over a 6-hour period.*

FDA Label Image

Figure 7 (Vardenafil Figure 8)

A line graph titled 'TAMSULOSIN' showing mean change in blood pressure (mmHg) over time (hours) with six different treatment conditions: placebo with 6-hour separation and simultaneous administration, and vardenafil 10 mg and 20 mg each with 6-hour separation and simultaneous administration. The graph plots mean change values from 0 to 10 mmHg on the y-axis over a 6-hour period on the x-axis for each condition.*

FDA Label Image

Figure 8 (Vardenafil Figure 9)

A line graph showing plasma concentration (µg/L) of Vardenafil Hydrochloride over time (hours). The graph depicts a peak concentration occurring within the first 2 hours, followed by a gradual decline in plasma concentration over 24 hours, with error bars indicating variability at each time point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.